title: High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.
abstract: OBJECTIVE
  A series of 53 patients with poor-prognosis epithelial ovarian cancer treated with high-dose chemotherapy (HDC) followed by hematopoietic rescue was retrospectively studied from the day of diagnosis for toxicity and long-term survival analysis.
  
  
  METHODS
  Patients were treated with surgery followed by cisplatin combination chemotherapy. After second-look operation (SLO), HDC was administered: 23 patients received melphalan (140 mg/m2 on day 1) and 30 patients received a combination of carboplatin (400 mg/m2 on days 1 to 4) and cyclophosphamide (1.6 g/m2 on days 1 to 4). After HDC, autologous stem-cell transplantation was performed for hematologic support.
  
  
  RESULTS
  One patient died of cardiac failure after HDC, but the acute toxicity was acceptable for the other patients. With a median follow-up of 81.5 months, the 5-year overall survival rate for the 53 patients was 59.9% and the disease-free survival (DFS) rate at 5 years was 23.6%. Twenty-four patients (45.3%) were alive, 12 with no evidence of disease and 12 with recurrent disease. The best results were achieved in 19 patients with pathologic complete response at SLO (74.2% 5-year overall survival; 32.8% 5-year DFS).
  
  
  CONCLUSIONS
  HDC followed by autologous stem-cell support is a well-tolerated therapeutic approach for patients with poor-prognosis ovarian carcinoma. In this report, the 59.9% survival of 53 patients at 5 years must be compared to the 20% to 30% 5-year survival observed after conventional therapy. These results should be confirmed by an ongoing prospective randomized trial.
authors.affiliation: Centre Jean Perrin, Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Legros
authors.forename: J
authors.initials: J
authors.lastname: Dauplat
authors.forename: J
authors.initials: J
authors.lastname: Fleury
authors.forename: H
authors.initials: H
authors.lastname: Cure
authors.forename: F
authors.initials: F
authors.lastname: Suzanne
authors.forename: J
authors.initials: J
authors.lastname: Chassagne
authors.forename: J O
authors.initials: JO
authors.lastname: Bay
authors.forename: C
authors.initials: C
authors.lastname: Sol
authors.forename: M
authors.initials: M
authors.lastname: Canis
authors.forename: P
authors.initials: P
authors.lastname: Condat
authors.forename: B
authors.initials: B
authors.lastname: Choufi
authors.forename: F
authors.initials: F
authors.lastname: Tavernier
authors.forename: C
authors.initials: C
authors.lastname: Glenat
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: R
authors.initials: R
authors.lastname: Plagne
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D016190:Carboplatin; D008558:Melphalan